Shenzhen New Industries Biomedical Engineering300832.SZValuation Analysis

As of Oct 19, 2026, Shenzhen New Industries Biomedical Engineering (300832.SZ) trades at a P/E of 23.10x, P/B of 4.42x, P/S of 8.18x, and a dividend yield of 2.38%.
Longitudinal percentile comparison: P/E sits at the 10th percentile over the trailing 10Y window (vs. 20th percentile over 3Y); P/B sits at the 10th percentile over the trailing 10Y window (vs. 19th percentile over 3Y); P/S sits at the 6th percentile over the trailing 10Y window (vs. 12th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 28th percentile within its industry and the 30th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.38%, ranking at the 82nd percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 0.3 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shenzhen New Industries Biomedical Engineering operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.